Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J/Cordis and Guidant arbitration

This article was originally published in The Gray Sheet

Executive Summary

Ruling on Lau patent disputes, in which Guidant asserts infringement by Cordis' BX Velocity and Omni BX stents, is expected in early 2004. Guidant's Lau patent infringement claims against J&J/Cordis will be the second patent issue decided under the firms' April 2000 stent patent arbitration and cross-licensing deal. An Aug. 20 arbitration panel upheld a June decision to award J&J/Cordis $425 mil. for the infringement of its Palmaz-Schatz patents by Guidant's Multi-Link Duet coronary stent system (1The Gray Sheet" June 9, 2003, p. 22). Guidant set aside the money following the initial ruling and will incur no further costs due to the cross-licensing arrangement...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel